Status:
COMPLETED
Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker
Lead Sponsor:
Sequenom, Inc.
Conditions:
Down Syndrome (Trisomy 21)
Edwards Syndrome (Trisomy 18)
Eligibility:
FEMALE
18+ years
Brief Summary
Validate that circulating cell free fetal nucleic acid can be used to identify a direct marker for fetal aneuploidy, particularly fetal Down Syndrome (DS), that is better than surrogate markers.
Eligibility Criteria
Inclusion
- Subject is female
- Subject is pregnant
- Subject is high risk aneuploid patient undergoing genetic counseling, unltrasound screening, amniocentesis and/or CVS procedure
- Subject is willing to provide blood specimen
Exclusion
- Subject is not pregnant
- Subject is not willing to provide blood specimen
- Subject is not haveing aneuploid screening
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00770458
Start Date
June 1 2008
End Date
December 1 2009
Last Update
January 6 2010
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSD Fetal Care & Genetics Center
La Jolla, California, United States, 92037
2
San Diego Perinatal Center
San Diego, California, United States, 92123
3
Obstetrix Medical Group of San Jose
San Jose, California, United States, 95008
4
Obstetrix Medical Group of Colorado
Denver, Colorado, United States, 80218